Breast microbiota and breast cancer： present and future

Abstract

Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.

References33

[1]	Mikó E, Kovács T, Sebő É, et al. Microbiome-microbial metabolome-cancer cell interactions in breast cancer-familiar, but unexplored[J].Cells,2019,8(4): 293. DOI:10.3390/cells8040293.
[2]	Dickson RP, Erb-Downward JR, Freeman CM, et al. Bacterial topography of the healthy human lower respiratory tract[J].mBio,2017,8(1): e02287-16. DOI:10.1128/mBio.02287-16.
[3]	Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria[J].Science,2020,368(6494): 973-980. DOI:10.1126/science.aay9189. pmid:32467386
[4]	Pushalkar S, Hundeyin M, Daley D, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression[J].Cancer Discov,2018,8(4): 403-416. DOI:10.1158/2159-8290.CD-17-1134. pmid:29567829
[5]	Banerjee S, Tian T, Wei Z, et al. Distinct microbial signatures associated with different breast cancer types[J].Front Microbiol,2018,9: 951. DOI:10.3389/fmicb.2018.00951. pmid:29867857
[6]	Uzan-Yulzari A, Morr M, Tareef-Nabwani H, et al. The intestinal microbiome, weight, and metabolic changes in women treated by adjuvant chemotherapy for breast and gynecological malignancies[J].BMC Med,2020,18(1): 281. DOI:10.1186/s12916-020-01751-2. pmid:33081767
[7]	Shui L, Yang X, Li J, et al. Gut microbiome as a potential factor for modulating resistance to cancer immunotherapy[J].Front Immunol,2019,10: 2989. DOI:10.3389/fimmu.2019.02989. pmid:32010123
[8]	Vitorino M, Alpuim Costa D, Vicente R, et al. Local breast microbiota: a "new" player on the block[J].Cancers (Basel),2022,14(15): 3811. DOI:10.3390/cancers14153811.
[9]	Tzeng A, Sangwan N, Jia M, et al. Human breast microbiome correlates with prognostic features and immunological signatures in breast cancer[J].Genome Med,2021,13(1): 60. DOI:10.1186/s13073-021-00874-2. pmid:33863341
[10]	Hieken TJ, Chen J, Chen B, et al. The breast tissue microbiome, stroma, immune cells and breast cancer[J].Neoplasia,2022,27: 100786. DOI:10.1016/j.neo.2022.100786.
[11]	Parida S, Sharma D. Microbial alterations and risk factors of breast cancer: connections and mechanistic insights[J].Cells,2020,9(5): 1091. DOI:10.3390/cells9051091.
[12]	Fu A, Yao B, Dong T, et al. Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer[J].Cell,2022,185(8): 1356-1372.e26. DOI:10.1016/j.cell.2022.02.027. pmid:35395179
[13]	Klann E, Williamson JM, Tagliamonte MS, et al. Microbiota composition in bilateral healthy breast tissue and breast tumors[J].Cancer Causes Control,2020,31(11): 1027-1038. DOI:10.1007/s10552-020-01338-5.
[14]	Smith A, Pierre JF, Makowski L, et al. Distinct microbial communities that differ by race, stage, or breast-tumor subtype in breast tissues of non-Hispanic Black and non-Hispanic White women[J].Sci Rep,2019,9(1): 11940. DOI:10.1038/s41598-019-48348-1. pmid:31420578
[15]	Pollet RM, D'Agostino EH, Walton WG, et al. An atlas of β-glucuronidases in the human intestinal microbiome[J].Structure,2017,25(7): 967-977.e5. DOI:10.1016/j.str.2017.05.003. pmid:28578872
[16]	Sellitto A, D'Agostino Y, Alexandrova E, et al. Insights into the role of estrogen receptor β in triple-negative breast cancer[J].Cancers (Basel),2020,12(6): 1477. DOI:10.3390/cancers12061477.
[17]	Shively CA, Register TC, Appt SE, et al. Consumption of Mediterranean versus Western diet leads to distinct mammary gland microbiome populations[J].Cell Rep,2018,25(1): 47-56.e3. DOI:10.1016/j.celrep.2018.08.078. pmid:30282037
[18]	Soto-Pantoja DR, Gaber M, Arnone AA, et al. Diet alters entero-mammary signaling to regulate the breast microbiome and tumorigenesis[J].Cancer Res,2021,81(14): 3890-3904. DOI:10.1158/0008-5472.CAN-20-2983. pmid:34083249
[19]	罗澜, 陈创, 李昕倩, 等. 细菌与乳腺癌的关系[J].国际肿瘤学杂志,2021,48(5): 292-295. DOI:10.3760/cma.j.cn371439-20200629-00056.
[20]	Giallourou N, Urbaniak C, Puebla-Barragan S, et al. Characterizing the breast cancer lipidome and its interaction with the tissue microbiota[J].Commun Biol,2021,4(1): 1229. DOI:10.1038/s42003-021-02710-0. pmid:34707244
[21]	Dadsena S, Hassan DG, Holthuis JCM. Unraveling the molecular principles by which ceramides commit cells to death[J].Cell Stress,2019,3(8): 280-283. DOI:10.15698/cst2019.08.196. pmid:31440742
[22]	Portincasa P, Bonfrate L, Vacca M, et al. Gut microbiota and short chain fatty acids: implications in glucose homeostasis[J].Int J Mol Sci,2022,23(3): 1105. DOI:10.3390/ijms23031105.
[23]	Schulthess J, Pandey S, Capitani M, et al. The short chain fatty acid butyrate imprints an antimicrobial program in macrophages[J].Immunity,2019,50(2): 432-445.e7. DOI:10.1016/j.immuni.2018.12.018. pmid:30683619
[24]	Salimi V, Shahsavari Z, Safizadeh B, et al. Sodium butyrate promotes apoptosis in breast cancer cells through reactive oxygen species (ROS) formation and mitochondrial impairment[J].Lipids Health Dis,2017,16(1): 208. DOI:10.1186/s12944-017-0593-4. pmid:29096636
[25]	Bagheri Z, Moeinzadeh L, Razmkhah M. Roles of microbiota in cancer: from tumor development to treatment[J].J Oncol,2022,2022: 3845104. DOI:10.1155/2022/3845104.
[26]	Chen F, Yang J, Guo Y, et al. Integrating bulk and single-cell RNA sequencing data reveals the relationship between intratumor microbiome signature and host metabolic heterogeneity in breast cancer[J].Front Immunol,2023,14: 1140995. DOI:10.3389/fimmu.2023.1140995.
[27]	Rao Malla R, Marni R, Kumari S, et al. Microbiome assisted tumor microenvironment: emerging target of breast cancer[J].Clin Breast Cancer,2022,22(3): 200-211. DOI:10.1016/j.clbc.2021.09.002.
[28]	Liwinski T, Zheng D, Elinav E. The microbiome and cytosolic innate immune receptors[J].Immunol Rev,2020,297(1): 207-224. DOI:10.1111/imr.12901. pmid:32658330
[29]	Pinato DJ, Howlett S, Ottaviani D, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer[J].JAMA Oncol,2019,5(12): 1774-1778. DOI:10.1001/jamaoncol.2019.2785. pmid:31513236
[30]	Kim H, Lee JE, Hong SH, et al. The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study[J].BMC Cancer,2019,19(1): 1100. DOI:10.1186/s12885-019-6267-z. pmid:31718585
[31]	Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J].Science,2018,359(6371): 91-97. DOI:10.1126/science.aan3706. pmid:29097494
[32]	Wang H, Rong X, Zhao G, et al. The microbial metabolite trime-thylamine N-oxide promotes antitumor immunity in triple-negative breast cancer[J].Cell Metab,2022,34(4): 581-594.e8. DOI:10.1016/j.cmet.2022.02.010. pmid:35278352
[33]	Geller LT, Barzily-Rokni M, Danino T, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine[J].Science,2017,357(6356): 1156-1160. DOI:10.1126/science.aah5043. pmid:28912244

Breast microbiota and breast cancer： present and future

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References33

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.
[3]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[4]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[5]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[6]	Liu Xiaodi, Su Jianfei, Zhang Jingxian, Wei Xueqin, Jia Yingjie.Research progress of myeloid-derived suppressor cells in tumor angiogenesis[J]. Journal of International Oncology, 2024, 51(1): 50-54.
[7]	Wang Jing, Xu Wenting.Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526.
[8]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531.
[9]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456.
[10]	Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462.
[11]	Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356.
[12]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[13]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng.Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance[J]. Journal of International Oncology, 2023, 50(4): 227-230.
[14]	Ding Hao, Ying Jintao, Fu Maoyong.Research progress of CAR-T in the treatment of esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(4): 231-235.
[15]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240.